M
Moni Sharma
Researcher at Central Drug Research Institute
Publications - 20
Citations - 795
Moni Sharma is an academic researcher from Central Drug Research Institute. The author has contributed to research in topics: 4-Aminoquinoline & Tetrazole. The author has an hindex of 13, co-authored 20 publications receiving 698 citations. Previous affiliations of Moni Sharma include Bhagwant University.
Papers
More filters
Journal ArticleDOI
Cyanuric Chloride Catalyzed Mild Protocol for Synthesis of Biologically Active Dihydro/Spiro Quinazolinones and Quinazolinone-glycoconjugates
TL;DR: An efficient cyanuric chloride catalyzed approach is developed for the synthesis of 2,3-dihydroquinazolin-4(1H)-one (3a-3x), 2-spiroquinazolone (5, 7), and glycoconjugates of 1,4,6-trichloro-1,3,5-triazine (10a, 10b) derivatives.
Journal ArticleDOI
Discovery of a new class of natural product-inspired quinazolinone hybrid as potent antileishmanial agents.
Moni Sharma,Kuldeep Chauhan,Rahul Shivahare,Preeti Vishwakarma,Manish Kumar Suthar,Abhisheak Sharma,Suman Gupta,Jitendra Kumar Saxena,Jawahar Lal,Preeti Chandra,Brijesh Kumar,Prem M. S. Chauhan +11 more
TL;DR: The results indicate that compounds 8a, 8g, and 9f represent a new structural lead for this serious and neglected disease.
Journal ArticleDOI
Substituted quinolinyl chalcones and quinolinyl pyrimidines as a new class of anti-infective agents.
Moni Sharma,Vinita Chaturvedi,Y.K. Manju,Shalini Bhatnagar,Kumkum Srivastava,Sunil K. Puri,Prem M. S. Chauhan +6 more
TL;DR: A comparison of structure-activity relationship reveals that different physicochemical and structural requirements exist for these two activities.
Journal ArticleDOI
Synthesis of oxalamide and triazine derivatives as a novel class of hybrid 4-aminoquinoline with potent antiplasmodial activity.
Naresh Sunduru,Moni Sharma,Kumkum Srivastava,S. Rajakumar,Surendra Puri,Jitendra Kumar Saxena,Prem M. S. Chauhan +6 more
TL;DR: 4-aminoquinolines having oxalamide and triazine functionalities in the side chain were synthesized and screened for their antimalarial activities and found to be the most active against CQ sensitive strain 3D7 of Plasmodium falciparum.
Journal ArticleDOI
Dihydrofolate reductase as a therapeutic target for infectious diseases: opportunities and challenges
Moni Sharma,Prem M. S. Chauhan +1 more
TL;DR: The challenges for novel DHFR inhibition-based chemotherapeutics for the treatment of infectious diseases are now focused on overcoming the resistance problem as well as cost-effectiveness.